International MPN News, Science & Opinion

Special Bulletin: Pacritinib

CTI

FDA Protecting

 

Partial return of pacritinib likely. 

FDA offers to tell all…with CTI’s permission.

CTI BioPharma declines.

February 29, 2016…. Richard Pazdur, the FDA’s oncology chief, offered to discuss openly reasons for placing a hold on pacritinib provided CTI authorized, in writing, the FDA’s disclosure of any and all clinical results.

CTI provided various reasons for its refusal. “The FDA,” said Senior VP Monique Greer, “has not yet shared its findings with CTI and the company has not seen the PERSIST2 data.”

Moreover, “unblinding the data prior to locking it down would place the study in jeopardy,” said Jack W. Singer, MD, CTI Chief Scientific Officer.

The clinical trial’s  independent Data Safety Monitoring Committee, according to Singer, MD,  concluded the trial should continue.  There are confirming reports of this conclusion. The DMSC reportedly also expressed concern over bleeding issues and sought more rigorous monitoring.

Only those with thrombocytopenia (platelet count ≤ 100,000/µL) qualified for the trial.  Without close scrutiny of the data – and perhaps even afterward — it is difficult to say whether myelofibrosis or pacritinib is responsible for bleeding and deaths on the clinical trial.

The bottom line: Pacrinitib is a drug that helps some and possibly harms others. Without hearing from the FDA why this Phase III drug that met with approvals through all its clinical trial stages was hit with a partial clinical hold and shortly afterward a full ban, we cannot know the full risk/benefit picture.

And without authorization from CTI BioPharma, the FDA will be unable to explain its actions despite the agency’s “frustration…at its inability to disclose” this information in the absence of formal, written consent by CTI BioPharma.

Without exception, every investigator we spoke with believes those patients who were deriving benefit from pacritinib should be allowed to continue taking the drug.  Many have been in touch with the FDA formally requesting immediate resumption of pacritinib to that population.

The reported FDA gesture – return to the partial hold of February 4 which would make pacritinib available to those already benefiting from the drug — has a morass of administrative detail attached.

Today,  Singer said the company would present the FDA-requested revised consent form to the agency  “early this week” and a proposal broadening the application to make the path for qualified patients to acquire pacritnib easier.

Unless there are revisions to the current FDA proposal, as it now stands each patient would have to qualify separately, acquire an independent NDA, and get approval of an Institutional Review Board. Moreover, none of this would apply to European patients.

Unfortunately for those with MF and very low platelet levels, there do not appear to be any good alternative meds.

Pacritinib is an oral tyrosine kinase inhibitor targeting two MPN mutations, JAK2 and CD135 or FLT-3, a protein frequently mutated in acute myeloid leukemia. The drug was widely seen as a possible alternative to Jakafi for myelofibrosis patients with very low platelets or anemia. After completing its Phase III PERSIST-I clinical trials, reported on favorably at ASCO and ASH in 2015, CTI readied its application for FDA approval in January, 2016.

After evaluation of PERSIST-2 trial data, the FDA placed a partial clinical hold on the drug February 4 followed on February 8 with a full clinical hold, essentially banning all use of the drug. Two weeks later FDA approached CTI to explore restoring the partial ban permitting pacritinib use by those clinical trial patients benefiting from the drug.

Contact FDA:  Toll Free (855) 543-3784, 

 

 

Take me back to the Contents

© 2016, MPNforum. All rights reserved under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License

Comments on: "Special Bulletin: Pacritinib" (5)

  1. I believe Phase 2 pacritinib trials only allowed people with ECOG status between 0 to 2. Phase 3 allowed inclusion of patients with ECOG 3 status. It is possible the inclusion of more debilitated patients led to more deaths and the resulting FDA hold (in addition to the crossover protocol inclusion). The deaths may never be directly linked to the drug however. Were dose investigations done on ECOG 3 patients in Phase 2? I believe not. Truth be told, as someone stated elsewhere, one reason drugs investigations have issues at Phase 3 is because of gross inadequacies in Phase 1 and 2.

    • Possibly, but whether not ECOG status was considered pacritinib Phase 3 trial used MPNSAF as inclusion criteria (Total Symptom Score ≥ 13 on the MPN-SAF TSS 2.0). You hit on the real problem, our inability to see the data and understand how FDA arrived at its action. Essentially issues of safety and dosage should have been resolved in Pahse I/II…although safety evaluation is an on-going process extending post approval. We’re all sufficiently different genetically that one size most definitely doesn’t fit all.

  2. Elizabeth Goldstein said:

    I wrote to the FDA at the link you provided. Their response was that it is illegal for them to give any information but I might try writing to
    CTI. Apparently, CTI is not going to cooperate and doesn’t want info revealed. If you think a letter to CTI would help, can you provide an email address? I have ET and don’t need this drug but will fight for those who do. We are all in this together.

    • That’s the spirit, Elizabeth. FDA may have sent you a boilerplate response but your inquiry was logged. And that inability to respond based on federal regulation is our next area to attack if we hope to win transparency and inclusiveness in clinical trials. We have to get some sunshine into the clinical trial process. For that we need political action.

      It’s a good idea to contact CTI. They are in a difficult place. I published their stated reasons to refuse open disclosure. I believe if they want to be forthright about their results and expedite the process of making pacritinib available they could find a path to accept the FDA’s offer. By all means write the company. mgreer@CTIBioPharma.com will get you to their communications chief. Their contact page has other contact points. http://www.ctibiopharma.com/about-us/contact-cti/ Good luck…and keep in touch.

  3. KAREN K. COLTRANE said:

    Please approve Pacritinib for patients on clinical trials that were seeing improvement.
    I also have primary myelofibrosis JAK2 POSITIVE (14 years currently).
    I have taken Jakafi for 2 years & because of anemia; maybe interested in Pacritinib in the future.
    Please approve this ASAP for others who have no alternative & were seeing improvement.
    Thank You!
    Karen Coltrane
    401 Oakmont Circle
    Archdale, NC

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: